Patents Represented by Attorney David W. Evans

Find this attorney in the Justia Lawyer Directory

  • Co-administration of a tissue plasminogen activator, anti-CD11b antibody and anti-CD18 antibody in stroke
    Patent number: 7655230
    Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: February 2, 2010
    Assignee: Genentech, Inc.
    Inventors: Martin M. Bednar, Cordell E. Gross, Linda J. Gross, legal representative, G. Roger Thomas
  • Human DNase
    Patent number: 7297526
    Abstract: DNA isolates coding for human DNase and methods of obtaining such DNA are provided, together with expression systems for recombinant production of human DNase useful in therapeutic or diagnostic compositions.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: November 20, 2007
    Assignee: Genentech, Inc.
    Inventor: Steven Shak
  • Compaction assay for assessment of respiratory disease therapy
    Patent number: 7193055
    Abstract: A compaction assay measuring the viscoelasticity of sputum samples of patients subject to respiratory disease is provided. This assay is useful in determining the therapeutic efficacy of DNase, antibiotic and other respiratory disease treatments in improving lung function.
    Type: Grant
    Filed: January 10, 2005
    Date of Patent: March 20, 2007
    Assignee: Genentech, Inc.
    Inventors: Ann L. Daugherty, Randy J. Mrsny, Thomas W. Patapoff
  • Serine protease inhibitors
    Patent number: 6919369
    Abstract: Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: July 19, 2005
    Assignee: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, Dean R. Artis, Michael S. Dina, John A. Flygare, Richard A. Goldsmith, Regina A. Munroe, Alan G. Olivero, Richard Pastor, Thomas E. Rawson, Kirk D. Robarge, Daniel P. Sutherlin, Kenneth J. Weese, Aihe Zhou, Yan Zhu
  • Amidine inhibitors of serine proteases
    Patent number: 6838479
    Abstract: Inhibitors of serine proteases are provided having formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein. In particular, the compounds bind to factor VIIa, tissue factor/factor Xa complex, thrombin, trypsin, plasmin and kallikrein and have anticoagulant activity. Pharmaceutical compositions comprising the compounds are useful for inhibiting the formation of veinous and/or arterial thrombi in vivo.
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: January 4, 2005
    Assignee: Genentech, Inc.
    Inventors: Richard M Pastor, Dean R. Artis, Alan G. Olivero
  • Serine protease inhibitors
    Patent number: 6472393
    Abstract: Compounds having the structure shown below wherein A, B, N1, N2, X, Y, Q, R2, R5 and R6 are as defined herein are useful to inhibit serine protease enzymes, such as TF/factor VIIa factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: October 29, 2002
    Assignee: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, Dean R. Artis, Michael S. Dina, John A. Flygare, Richard A. Goldsmith, Regina A. Munroe, Alan G. Olivero, Richard Pastor, Thomas E. Rawson, Kirk D. Robarge, Daniel P. Sutherlin, Kenneth J. Weese, Aihe Zhou, Yan Zhu
  • Purified forms of DNase
    Patent number: 6440412
    Abstract: The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: August 27, 2002
    Assignee: Genentech, Inc.
    Inventors: John Frenz, Steven J. Shire, Mary B. Sliwkowski
  • Human DNase I variants
    Patent number: 6348343
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have reduced binding affinity for actin. The invention provides nucleic acid sequences encoding such actin-resistant variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of actin-resistant variants of human DNase I.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: February 19, 2002
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Steven Shak, Jana S. Ulmer